{"disease":{"id":"women","name":"women"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"menest","indication_name":"Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Adjuvant chemotherapy for women with axillary lymph node involvement following resection of primary breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of osteoporosis in postmenopausal women at high risk of fracture","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of advanced breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"adjuvant-letrozole-postmenopausal-women","indication_name":"Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adjuvant letrozole (postmenopausal women)","generic_name":"adjuvant-letrozole-postmenopausal-women","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"aromatase","drug_class":"aromatase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in postmenopausal women with disease progression following prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menotropins","indication_name":"Development of multiple follicles and pregnancy in ovulatory women","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menopur","generic_name":"MENOTROPINS","company_name":"Ferring","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"MENOPUR promotes ovarian follicular growth and maturation, requiring hCG for ovulation."},{"drug_id":"menotropins","indication_name":"Development of multiple follicles and pregnancy in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menopur","generic_name":"MENOTROPINS","company_name":"Ferring","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"MENOPUR promotes ovarian follicular growth and maturation, requiring hCG for ovulation."},{"drug_id":"cefpodoxime","indication_name":"Acute, uncomplicated ano-rectal infections in women","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":102,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06641479","title":"JiAngSu Maternal and INfant HEalth Database","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1570360,"lead_sponsor_name":"Yang Zhao","has_results":false},{"nct_id":"NCT06999317","title":"CARAMEL: Retrospective Study for Personalized Risk Assessment of Cardiovascular Disease in Menopausal and Perimenopausal Women Using Real World Data","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Hospital Universitario Virgen Macarena","has_results":false},{"nct_id":"NCT06422130","title":"Ningbo Maternity-Child Linked Database Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":325596,"lead_sponsor_name":"Ningbo University","has_results":false},{"nct_id":"NCT03099889","title":"WHISH-2-Prevent Heart Failure","phase":"NA","overall_status":"UNKNOWN","enrollment_count":49936,"lead_sponsor_name":"Memorial Hospital of Rhode Island","has_results":false},{"nct_id":"NCT05509049","title":"Precision Nudging Drives Wellness Visit Attendance at Scale","phase":"NA","overall_status":"COMPLETED","enrollment_count":30068,"lead_sponsor_name":"Lirio","has_results":false},{"nct_id":"NCT05489536","title":"Optimizing Gestational Weight Gain for Prevention of Gestational Diabetes Mellitus in Malaysia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Universiti Putra Malaysia","has_results":false},{"nct_id":"NCT02104817","title":"Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13078,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06733155","title":"Trial to Evaluate the Impact of Various Interventions to Increase the Uptake of Surveillance Mammography in Eligible Women in Singapore","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":12000,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT03280680","title":"Right to Health and Freedom From Violence","phase":"NA","overall_status":"COMPLETED","enrollment_count":11340,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT03848962","title":"Collection and Distribution of Biospecimens for Novel Research Uses","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"iSpecimen Inc","has_results":false},{"nct_id":"NCT06291896","title":"A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Umbria Bioengineering Technologies","has_results":false},{"nct_id":"NCT07283107","title":"Trial to Evaluate the Impact of Various Behavioural Interventions to Increase Mammography Uptake Among Singaporean Women","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":8910,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT03708978","title":"Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography","phase":"","overall_status":"COMPLETED","enrollment_count":5809,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05776082","title":"Association of Gestational Cardiovascular Health With Pregnancy Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT06756165","title":"Community Based Mental Health Screening and Referral","phase":"NA","overall_status":"COMPLETED","enrollment_count":4800,"lead_sponsor_name":"Dr Jai Kumar Das","has_results":false},{"nct_id":"NCT01631214","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4093,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05349279","title":"Qatar PREgnancy Covid-19 OUtcome Study","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Hamad Medical Corporation","has_results":false},{"nct_id":"NCT00341302","title":"A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries","phase":"","overall_status":"COMPLETED","enrollment_count":3554,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT05750368","title":"Long-term Outcomes After Epigastric Hernia Repair in Women - a Nationwide Database Study","phase":"","overall_status":"COMPLETED","enrollment_count":3031,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT06845423","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT02156219","title":"Impact Evaluation of Separating Women and Men in the Metro of Mexico City","phase":"","overall_status":"SUSPENDED","enrollment_count":2360,"lead_sponsor_name":"Econometría Consultores","has_results":false},{"nct_id":"NCT03580512","title":"Study to Evaluate the Feasibility of Integrating the Point-of-care Testing for Sexually Transmitted Infections and HIV Into Community-based Clinics for MSM and TGW in Thailand","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Thai Red Cross AIDS Research Centre","has_results":false},{"nct_id":"NCT03668977","title":"Balanced Protein-Energy Supplement in Pregnancy and Early Lactation on Birth Outcomes and Growth in Southern Nepal","phase":"NA","overall_status":"COMPLETED","enrollment_count":1944,"lead_sponsor_name":"George Washington University","has_results":false},{"nct_id":"NCT03633799","title":"Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1620,"lead_sponsor_name":"Sebela Women's Health Inc.","has_results":true},{"nct_id":"NCT07238608","title":"Impact of UFPs and MNPs on Fetal Health","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Instituto de Investigacion Sanitaria La Fe","has_results":false},{"nct_id":"NCT03511118","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05598697","title":"Economic Evaluation of the MEWE Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":1536,"lead_sponsor_name":"London School of Economics and Political Science","has_results":false},{"nct_id":"NCT04457076","title":"Evaluation of the Efficacy, Safety, and Tolerability of LevoCept","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1525,"lead_sponsor_name":"Sebela Women's Health Inc.","has_results":false},{"nct_id":"NCT06864130","title":"A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT04957953","title":"Pregnant Women Vaccinated Against Covid-19.","phase":"","overall_status":"COMPLETED","enrollment_count":1393,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07209722","title":"PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare","phase":"","overall_status":"COMPLETED","enrollment_count":1377,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT07031557","title":"Pregnancy and Lactation- Associated Osteoporosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1230,"lead_sponsor_name":"Parma University Hospital","has_results":false},{"nct_id":"NCT03265626","title":"Community Based Intervention to Prevent Domestic Violence Against Women in Ethiopia; a Protocol for Quasi-Experimental Implementation Research","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1217,"lead_sponsor_name":"Haramaya Unversity","has_results":false},{"nct_id":"NCT03464669","title":"Impacts of Online and Group Perinatal Education","phase":"","overall_status":"COMPLETED","enrollment_count":1208,"lead_sponsor_name":"CHU de Quebec-Universite Laval","has_results":false},{"nct_id":"NCT04277013","title":"Ultrasound Assessment of Gastric Content in Fasted Pregnant Women","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT07382947","title":"MENSTRUATİON MANAGEMENT ACCORDİNG TO GENERATİONS","phase":"NA","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Batman University","has_results":false},{"nct_id":"NCT07524764","title":"Female Reproductive Health in Canadian Armed Forces","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1121,"lead_sponsor_name":"Université de Sherbrooke","has_results":false},{"nct_id":"NCT03124160","title":"Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1105,"lead_sponsor_name":"FHI 360","has_results":true},{"nct_id":"NCT03699150","title":"Cardio-metabolic Risk Factors, Osteoporosis and Thrombus Embolic Assessment, Along Woman's Life","phase":"","overall_status":"COMPLETED","enrollment_count":1100,"lead_sponsor_name":"Silvia Maffei","has_results":false},{"nct_id":"NCT03093194","title":"Vaginal Antimicrobacterial Preparation Before Cesarean Secation for Endometritis Prevention","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1040,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT03907332","title":"Using Community Health Nurses and Workers for Home Visits to Pregnant Women to Improve Maternal and New Born Health in Ghana","phase":"NA","overall_status":"COMPLETED","enrollment_count":952,"lead_sponsor_name":"Ghana Health Services","has_results":false},{"nct_id":"NCT03949829","title":"The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":921,"lead_sponsor_name":"Klaus Fuglsang Kofoed","has_results":false},{"nct_id":"NCT03955263","title":"Malaria In Pregnancy in Central India","phase":"","overall_status":"UNKNOWN","enrollment_count":887,"lead_sponsor_name":"Lata Medical Research Foundation, Nagpur","has_results":false},{"nct_id":"NCT05786482","title":"Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":825,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT04821492","title":"Relationship Between Homocysteine and BMD","phase":"","overall_status":"COMPLETED","enrollment_count":760,"lead_sponsor_name":"Fundación Santiago Dexeus Font","has_results":false},{"nct_id":"NCT01277029","title":"Study of Psychiatric Aspects in Women With Lower Urinary Tract Symptoms","phase":"","overall_status":"COMPLETED","enrollment_count":702,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT06656611","title":"Mobile Outreach Screening of High-Risk Human Papillomavirus Infection in Women with Limited Access to Health Services in Seine-Saint-Denis (greater Paris Area, France)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","has_results":false},{"nct_id":"NCT04989673","title":"Materno-fetal Consequences of Symptomatic Dengue in Pregnant Wowen in French Guiana","phase":"","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"Centre Hospitalier de Cayenne","has_results":false},{"nct_id":"NCT03651934","title":"Verification of Correlation Between Genetic Testing of Nutritional Metabolism and Clinical Biochemical Indicators","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04925180","title":"A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Bayer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}